Biotech Specialty Pharma

Syndax Pharmaceuticals

460, Totten Pond Road, Suite 650
Waltham, MA 02451 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Developing and commercializing novel therapies for cancer patients.

Management Joanna Horobin, MD, President & Chief Executive Officer; Robert Goodenow, PhD, Chief Business Officer; Gloria Lee, M.D., Ph.D., Vice President of Clinical Development; Miranda M.C. Rees, Vice President, Product Development; Peter Ordentlich, PhD, Director, Scientific Affairs/Strategic Relations & Founder

Click here for Financial Data
Keywords: lung cancer, tumor phenotype, hdac inhibitor, clinic, renal cell cancer


Updated: Oct. 12, 2011


Syndax Pharmaceuticals, Inc., was founded in 2005 to extend and improve the lives of cancer patients by developing and commercializing novel therapies. Their vision is to modify the tumor phenotype, a......view more

Technology / Differentiation

Histone deacetylase (HDAC) inhibitors are excellent candidates to test the therapeutic potential of tumor phenotype modification. Based on a robust preclinical platform and multiple Phase 2 clinical s...view more